Toby Trahair

Featured in: Favicon

Articles

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia - Blood Cancer Journal

Nov 5, 2024 | nature.com | Hansen Kosasih |Chelsea Mayoh |Michelle Henderson |Toby Trahair |Adam Patterson

AbstractT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the enzyme aldo-keto reductase family 1 member C3 (AKR1C3). To exploit this finding, we developed a novel prodrug, ACHM-025, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent.
Precision-guided treatment in high-risk pediatric cancers - Nature Medicine

Jun 6, 2024 | nature.com | Dong-Anh Khuong-Quang |Chelsea Mayoh |Marie Wong |Sumanth Nagabushan |Veronica Yeung |Natacha Omer | +15 more

AbstractRecent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT).
Precision-guided treatment in high-risk pediatric cancers - Nature Medicine

Jun 6, 2024 | nature.com | Dong-Anh Khuong-Quang |Chelsea Mayoh |Marie Wong |Sumanth Nagabushan |Veronica Yeung |Natacha Omer | +15 more

AbstractRecent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT).

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.